PRAXIS PRECISION MEDICINES, INC. Proceeds from Sale and Maturity of Marketable Securities
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Proceeds from Sale and Maturity of Marketable Securities of $231.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $89.27M, a 50.54% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $142.57M, a 116.04% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $61.88M, a 5.78% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $125.55M, a 104.06% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $312.72M, a 154.19% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $123.03M, a 215.45% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $39.00M, a 78.38% decline from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $180.35M, a 630.18% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $231.84M 10-Q · filed 2026-08-06 | $293.72M derived: sum of 3 quarters · filed 2026-08-06 | $419.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $142.57M 10-Q · filed 2026-05-07 | $204.45M derived: sum of 2 quarters · filed 2026-05-07 | $330.00M derived: sum of 3 quarters · filed 2026-05-07 | $389.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $61.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $187.43M derived: sum of 2 quarters · filed 2026-02-19 | $246.73M derived: sum of 3 quarters · filed 2026-08-06 | $312.72M 10-K · filed 2026-02-19 |
| 2025-09-30 | $125.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $184.84M derived: sum of 2 quarters · filed 2026-08-06 | $250.84M 10-Q · filed 2025-11-05 | $309.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $59.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $125.29M 10-Q · filed 2026-08-06 | $183.79M derived: sum of 3 quarters · filed 2026-08-06 | $245.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $65.99M 10-Q · filed 2026-05-07 | $124.49M derived: sum of 2 quarters · filed 2026-05-07 | $186.02M derived: sum of 3 quarters · filed 2026-05-07 | $189.02M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $58.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $120.03M derived: sum of 2 quarters · filed 2026-02-19 | $123.03M derived: sum of 3 quarters · filed 2026-02-19 | $123.03M 10-K · filed 2026-02-19 |
| 2024-09-30 | $61.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $64.53M derived: sum of 2 quarters · filed 2025-11-05 | $64.53M 10-Q · filed 2025-11-05 | $64.53M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $3.00M 10-Q · filed 2025-08-04 | $3.00M derived: sum of 3 quarters · filed 2026-02-19 | $3.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-02 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $5.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $5.00M derived: sum of 3 quarters · filed 2026-02-19 | $39.00M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.00M derived: sum of 2 quarters · filed 2024-11-06 | $39.00M 10-Q · filed 2024-11-06 | $61.59M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $39.00M 10-Q · filed 2024-08-13 | $61.59M derived: sum of 3 quarters · filed 2024-08-13 | $109.59M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $34.00M 10-Q · filed 2024-05-13 | $56.59M derived: sum of 2 quarters · filed 2024-05-13 | $104.59M derived: sum of 3 quarters · filed 2024-05-13 | $139.59M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $22.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $70.59M derived: sum of 2 quarters · filed 2024-03-05 | $105.59M derived: sum of 3 quarters · filed 2024-03-05 | $180.35M 10-K · filed 2024-03-05 |
| 2022-09-30 | $48.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $83.00M derived: sum of 2 quarters · filed 2023-11-07 | $157.76M 10-Q · filed 2023-11-07 | $168.46M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $109.76M 10-Q · filed 2023-08-09 | $120.46M derived: sum of 3 quarters · filed 2023-08-09 | $134.46M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $74.76M 10-Q · filed 2023-05-11 | $85.46M derived: sum of 2 quarters · filed 2023-05-11 | $99.46M derived: sum of 3 quarters · filed 2023-05-11 | $99.46M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $24.70M derived: sum of 2 quarters · filed 2023-02-07 | $24.70M derived: sum of 3 quarters · filed 2023-02-07 | $24.70M 10-K · filed 2023-02-07 |
| 2021-09-30 | $14.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $14.00M derived: sum of 2 quarters · filed 2022-11-09 | $14.00M 10-Q · filed 2022-11-09 | $14.00M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2022-08-08 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |